Cooperative Agreement IDSEP150027

This $175,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a decentralized antimicrobial resistance (AMR) surveillance system for monitoring drug-resistant bacteria in resource-limited settings. The 4-year project will assess the use of cost-effective long-read sequencing techniques, leveraging Flongle sequencing platforms, to detect drug-resistant...

This Project Grant award for $490,093 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel microfluidic-enabled platform for rapid antibiotic susceptibility testing. The University of Maryland, College Park will use this funding to create a system that can isolate bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response...

This Project Grant award of $2,308,174 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to develop new antibiotic combinations to combat the threat of carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The key products and services being delivered include: Gaining mechanistic insights into antibiotic resistance and persister cell formation to enable the rational design of optimized antibiotic...

This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is providing $1,148,000.00 to The Trustees of Princeton University to develop novel approaches for combating bacterial infections and antibiotic resistance. The key innovation is a breakthrough single-cell RNA sequencing method called M3-SEQ that enables monitoring of bacterial and host gene expression dynamics during infections at...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) Project Grant award of $305,000 to Resonantia Diagnostics, Inc. aims to develop a rapid point-of-care diagnostic platform capable of identifying pathogens and determining their antimicrobial susceptibility within 60 minutes. The project will focus on advancing an acoustic sensing technology to: (1) demonstrate accurate antimicrobial susceptibility testing at low pathogen loads, (2)...

This Project Grant award of $275,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The award recipient, Informuta, Inc., will establish the feasibility of leveraging mutational signatures found in bacterial DNA to predict antibiotic resistance status. The project aims to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $241,500 to New York University (NYU) to develop a high-throughput screening approach to discover protein-based efflux pump inhibitors (EPIs). The goal is to identify compounds that can block antibiotic resistance mechanisms in pathogenic bacteria without the need for sample optimization, thereby expediting the...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $392,634 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin-Madison on May 13, 2025. The funding supports the development of a novel broad-spectrum nanoimmunotherapeutic approach for combating multidrug-resistant (MDR) bacterial infections, particularly those caused by the ESKAPE pathogens. The project aims to design, fabricate, and optimize a...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to support research focused on developing novel antibiotics to address the growing problem of multi-drug resistant pathogens. The research aims to synthesize and biologically evaluate a modular platform of antibiotics that target the localization of lipoproteins (Lol) pathway in gram-negative bacteria,...

This $305,000 SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) was granted to Giant Biosystems Inc., a small disadvantaged business, to develop a rapid point-of-care antimicrobial susceptibility testing (AST) kit. The key products to be delivered include: A novel microfluidic platform for rapid (6-9 hours) and precise AST, providing actionable results faster than current methods (3-5 days). This will enable...